Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation. — CFSMEATLAS
Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
Eaton, Natalie, Cabanas, Hélène, Balinas, Cassandra et al. · BMC pharmacology & toxicology · 2018 · DOI
Quick Summary
This study examined how a drug called Rituximab affects natural killer (NK) cells—immune cells that help fight infections—in people with ME/CFS. Researchers tested blood samples from 8 ME/CFS patients and 9 healthy people in a lab dish. When exposed to Rituximab, NK cells from ME/CFS patients became less effective at killing infected cells and showed signs of stress, suggesting the drug might harm these already-weakened immune cells.
Why It Matters
ME/CFS patients already have impaired NK cell function, and this study raises safety concerns about Rituximab as a potential treatment. Understanding how proposed therapies affect immune cells is critical for patient safety and for developing treatments that don't inadvertently worsen immune dysfunction.
Observed Findings
Rituximab at 100 μg/ml significantly reduced NK cell lysis in CFS/ME patients compared to controls at both 12.5:1 and 6.25:1 E:T ratios
Granzyme B expression was significantly decreased in CFS/ME patients exposed to 100 μg/ml Rituximab prior to target cell stimulation
CD107b degranulation markers increased significantly in both groups following 100 μg/ml Rituximab exposure with K562 cell stimulation
No significant effects were observed in healthy controls at 10 μg/ml Rituximab concentration
CFS/ME patients showed baseline differences in CD107b expression even without Rituximab exposure
Inferred Conclusions
Rituximab may be toxic to NK cells in ME/CFS patients, impairing their ability to kill infected cells
Caution should be exercised before using Rituximab in clinical trials for ME/CFS treatment
Further in vitro and in vivo investigation is needed before progressing to clinical applications
The differential effects between CFS/ME patients and healthy controls suggest disease-specific vulnerability to Rituximab's immunological effects
Remaining Questions
Would these in vitro findings translate to clinical harm in actual ME/CFS patients receiving Rituximab treatment?
What This Study Does Not Prove
This study does not prove that Rituximab causes harm in ME/CFS patients in clinical practice—it only examines isolated cells in a lab dish at specific drug concentrations. The findings cannot be directly translated to what would happen in a patient's body, and the study does not assess clinical outcomes or long-term effects. Laboratory findings at high concentrations may not occur at therapeutic doses used in patients.